OOIR: Observatory of International Research

Papers

(The TQCC of Current Opinion in Oncology is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)

Article	Citations
The impact of new and emerging agents on outcomes for febrile neutropenia: addressing clinical gaps	55
The road to chemotherapy-free treatment in chronic lymphocytic leukaemia	38
Can febrile neutropenia re-invent its self?	32
Challenges adopting next-generation sequencing in community oncology practice	30
First and further-line multidisciplinary treatment of retroperitoneal sarcomas	28
Angiogenesis inhibition in lung cancer: emerging novel strategies	26
Pathologic diagnosis of lung cancer – recent developments	25
Treatment of anaplastic gliomas: evidences and controversies	21
Hepatosplenic T-cell lymphoma: treatment challenges	21
Editorial introductions	20
Editorial: Head and neck squamous cell cancer: ways to optimize the treatment and improve the outcomes	19
Opportunities and challenges of neoadjuvant targeted therapy in nonsmall cell lung cancer	17
Progress in diagnosis and treatment of checkpoint inhibitor pneumonitis	17
Editorial introductions	17
Robot-assisted laparoscopic staging compared to conventional laparoscopic staging and laparotomic staging in clinical early stage ovarian carcinoma	16
Breast surgery after neoadjuvant therapy	16
Psycho-oncology interventions focusing on fatigue and sleep disturbances	15
Postneoadjuvant treatment for triple-negative breast cancer	15
Bacterial infection-driven lymphomagenesis	15
Deciphering diffuse glioma immune microenvironment as a key to improving immunotherapy results	14
Mind the target: human epidermal growth factor receptor 2 in colorectal cancer	13
Treatments and challenges in advanced prostate cancer	13
Editorial: Psychological interventions in oncology: advances and challenges	13
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	13
Preclinical glioma models in neuro-oncology: enhancing translational research	12

Adjuvant and neoadjuvant approaches in pancreatic cancer	12
Evolving systemic management of urothelial cancers	12
New strategies for the treatment of breast cancer with leptomeningeal metastasis	12
Neurorehabilitation in brain tumours: evidences and suggestions for spreading of knowledge and research implementation	11
State of the art and upcoming trends in HER2-directed therapies in gastrointestinal malignancies	10
Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology	10
Antibody-drug conjugates in solid tumors: a new frontier	10
New targeted therapies in liposarcoma: state of art and future perspectives	10
Survivorship after Hodgkin lymphoma and the right to be forgotten	10
Circulating tumour DNA dynamics for assessment of molecular residual disease and for intercepting resistance in breast cancer	9
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer	9
Content features and its implementation in novel app-based psycho-oncological interventions for cancer survivors: a narrative review	9
The role of signaling lymphocyte activation molecule family receptors in hematologic malignancies	9
New treatments for desmoid tumors	9
The multiple molecular dimensions of long noncoding RNAs that regulate gene expression and tumorigenesis	9
Is there still a place for lymph node dissection for stage III melanoma since the approval of adjuvant therapy	8
Controversies on chemotherapy for early HR+/HER2− breast cancer: the role of anthracyclines and dose intensification	8
Neoadjuvant immunotherapy in melanoma: pathological response as a surrogate endpoint?	8
Genomic tests for risk stratification in patients with early human epidermal growth factor receptor 2-positive breast cancer	8
Epigenetic dynamics of aging and cancer development: current concepts from studies mapping aging and cancer epigenomes	8
HTLV-1-related adult T-cell leukemia/lymphoma: insights in early detection and management	7
Unveiling the enigma of the blood–brain barrier in glioblastoma: current advances from preclinical and clinical studies	7
Advances in the treatment of light chain amyloidosis	7
Burnout among health professionals working in oncology: current evidence and challenges for future research	7
Harnessing dendritic cells for innovative therapeutic cancer vaccines	7
Novel immunotherapy combinations in head and neck squamous cell carcinoma	7
Nanoparticle therapy for head and neck cancers	7
Novel PET tracers in breast cancer for treatment optimization: clinical utility and future perspectives	7
Anal squamous cell carcinoma: standards of care, new data and ongoing clinical trials	7
Role of PSMA PET/CT in imaging and management of prostate cancer	7
Pathology and new insights in thyroid neoplasms in the 2022 WHO classification	7
Editorial introductions	6
BRAF mutations in thyroid cancer	6
Recent advances in allogeneic transplantation for acute myeloid leukemia	6
The roaring 2020s: a new decade of systemic therapy for renal cell carcinoma	6
Targeting SUMOylation in cancer	6
Immunotherapy for inflammatory breast cancer: current evidences and future perspectives	6
HER2-positive breast cancer: cotargeting to overcome treatment resistance	6
Targeting cancer stem cell pathways for lung cancer therapy	6
Integrating new oral selective oestrogen receptor degraders in the breast cancer treatment	6
The role of biomarkers in the management of HPV-related oropharyngeal cancer	6
Editorial: Supportive care in cancer patients: quo vadis?	6
Two is company, is three a crowd? Triplet therapy, novel molecular targets, and updates on the management of advanced renal cell carcinoma	6
2024 ASCO guidelines for the prevention and management of osteoradionecrosis in patients with head & neck cancer treated with radiation therapy	6
Challenges in the management of relapsed germ cell tumors	5
Local treatment in patients with hereditary breast cancer: decision-making process in low-, moderate-, high-penetrance pathogenic germline mutation carriers	5
New horizons in early drugs development in solid cancers	5
Editorial introductions	5
Prophylactic cranial irradiation in small cell lung cancer: an update	5
State of the art and future directions in the systemic treatment of medullary thyroid cancer	5

Editorial: precision medicine of sarcomas and aggressive connective tissue tumours: from one-size-fits-all to haute couture	5
How to prevent human papillomavirus-related oropharyngeal cancer?	5
Venetoclax in combination with nucleoside analogs in acute myelogenous leukemia	5
Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?	5
Impact of sentinel node implementation in gynecologic cancers	5
New molecular entities of soft tissue and bone tumors	5
Image-guided surgery in oral cancer: toward improved margin control	5
Question prompt lists to improve communication between cancer patients and healthcare professionals	5
Safety of assisted reproductive techniques in gynecological cancer patients	5
Editorial introductions	5
Editorial introductions	5
WHO 2021 and beyond: new types, molecular markers and tools for brain tumor classification	5
Surgical management of skull base meningiomas and vestibular schwannomas	5
New hopes in relapsed refractory primary central nervous system lymphoma	5
CIC-DUX4 sarcomas	5
Treatment of radiation-associated angiosarcoma	4
Impact of sentinel node use in lymphedema formation among gynecologic cancer patients	4
Beyond ‘the good, the bad and the ugly’: let us put rectal cancer patients at the centre of the decision making	4
Advances in the pathogenesis of FLT3-mutated acute myeloid leukemia and targeted treatments	4
Bromodomain and extraterminal domain protein bromodomain inhibitor based cancer therapeutics	4
Immune checkpoint inhibitors in driver mutation-positive nonsmall cell lung cancer	4
Tropomyosin receptor kinases in sarcomas – of joy and despair	4
Sarcoma incidence worldwide: regional differences in histology and molecular subtypes	4
Editorial: Advanced care planning	4
Stereotactic ablative radiation therapy in metastatic prostate cancer	4
Benefits of sentinel node detection in cervical cancer	4
Application of natural killer immunotherapy in blood cancers and solid tumors	4
Ten steps to establish a national centre for gestational trophoblastic disease	4
Is less more in the surgical treatment of early-stage cervical cancer?	4
Novel therapeutics in refractory germ cell tumors	4
Neoadjuvant and adjuvant approaches in gastroesophageal cancers	4
When do I ask for a DNA methylation array for primary brain tumor diagnosis?	4
Immunotherapy in first line treatment of adult acute lymphoblastic leukemia	4
State-of-the-art and trends in fibroblast growth factor receptor-directed therapies in gastro-intestinal malignancies	4
Unveiling the role of cellular dormancy in cancer progression and recurrence	4
Are advancements in screening technology contributing to breast cancer over-diagnosis?	4
Recent advances in radiosensitivity determinants in melanoma	4
Educational needs of self-care in cachectic cancer patients and caregivers	4
Biomarkers and immunotherapy: where are we?	4
Biomarker-directed therapy in multiple myeloma	4